Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Oct;36(10):2192–2196. doi: 10.1128/aac.36.10.2192

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

F de Lalla 1, R Nicolin 1, E Rinaldi 1, P Scarpellini 1, R Rigoli 1, V Manfrin 1, A Tramarin 1
PMCID: PMC245474  PMID: 1444298

Abstract

A prospective, randomized study comparing oral teicoplanin with oral vancomycin in the treatment of pseudomembranous colitis (PMC) and Clostridium difficile-associated diarrhea (CDAD) was performed. Teicoplanin was administered at a dosage of 100 mg twice a day for 10 days, and vancomycin was administered at a dosage of 500 mg four times a day for 10 days. CDAD was diagnosed by demonstrating both C. difficile and cytotoxin in the feces of symptomatic patients (more than three loose stools per day). The diagnosis of PMC was also based on colonoscopy. Cytotoxin assay and cultures were checked in all patients 7 to 10 days after discontinuation of therapy and 25 to 30 days thereafter. Of the 51 patients enrolled, 46 were judged to be assessable. Among these, 26 received teicoplanin and 20 received vancomycin. At enrollment, both groups were comparable in terms of age, sex, occurrence of PMC or CDAD, and previous antibiotic treatment. Eighteen of the 20 patients in the vancomycin group and 10 of the 26 patients in the teicoplanin group had previously undergone surgery (P = 0.0004). Treatment resulted in the clinical cure of 20 (100%) vancomycin and 25 (96.2%) teicoplanin patients (P = 0.56). After discontinuation of therapy, clinical symptoms recurred in four (20%) vancomycin patients and two (7.7%) teicoplanin patients (P = 0.21). Posttherapy asymptomatic C. difficile carriage (positive follow-up cultures without any clinical symptoms) occurred in five (25%) vancomycin patients and two (7.7%) teicoplanin patients (P = 0.11).Overall, 9 of 20 (45%) vancomycin patients and 5 of 26 (19.2%) teicoplanin patients (P=0.059) appeared not to be cleared of C. difficile after treatment. No adverse effects related to vancomycin or teicoplanin therapy were observed.

Full text

PDF
2192

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett J. G., Tedesco F. J., Shull S., Lowe B., Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology. 1980 Mar;78(3):431–434. [PubMed] [Google Scholar]
  2. Bender B. S., Bennett R., Laughon B. E., Greenough W. B., 3rd, Gaydos C., Sears S. D., Forman M. S., Bartlett J. G. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986 Jul 5;2(8497):11–13. doi: 10.1016/s0140-6736(86)92559-6. [DOI] [PubMed] [Google Scholar]
  3. Biavasco F., Manso E., Varaldo P. E. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 1991 Jan;35(1):195–197. doi: 10.1128/aac.35.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buchanan A. G. Selective enrichment broth culture for detection of Clostridium difficile and associated cytotoxin. J Clin Microbiol. 1984 Jul;20(1):74–76. doi: 10.1128/jcm.20.1.74-76.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clabots C. R., Peterson L. R., Gerding D. N. Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing. J Infect Dis. 1988 Oct;158(4):731–736. doi: 10.1093/infdis/158.4.731. [DOI] [PubMed] [Google Scholar]
  6. Corti A., Cavenaghi L., Giani E., Cassani G. A receptor-antibody sandwich assay for teicoplanin. Clin Chem. 1987 Sep;33(9):1615–1618. [PubMed] [Google Scholar]
  7. Cumming A. D., Thomson B. J., Sharp J., Poxton I. R., Fraser A. Diarrhoea due to Clostridium difficile associated with antibiotic treatment in patients receiving dialysis: the role of cross infection. Br Med J (Clin Res Ed) 1986 Jan 25;292(6515):238–239. doi: 10.1136/bmj.292.6515.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Delmee M., Bulliard G., Simon G. Application of a technique for serogrouping Clostridium difficile in an outbreak of antibiotic-associated diarrhoea. J Infect. 1986 Jul;13(1):5–9. doi: 10.1016/s0163-4453(86)92095-5. [DOI] [PubMed] [Google Scholar]
  9. Delmee M., Homel M., Wauters G. Serogrouping of Clostridium difficile strains by slide agglutination. J Clin Microbiol. 1985 Mar;21(3):323–327. doi: 10.1128/jcm.21.3.323-327.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Delmée M., Vandercam B., Avesani V., Michaux J. L. Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol. 1987 Dec;6(6):623–627. doi: 10.1007/BF02013056. [DOI] [PubMed] [Google Scholar]
  11. Fekety R., Kim K. H., Brown D., Batts D. H., Cudmore M., Silva J., Jr Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med. 1981 Apr;70(4):906–908. doi: 10.1016/0002-9343(81)90553-2. [DOI] [PubMed] [Google Scholar]
  12. Fekety R. Recent advances in management of bacterial diarrhea. Rev Infect Dis. 1983 Mar-Apr;5(2):246–257. doi: 10.1093/clinids/5.2.246. [DOI] [PubMed] [Google Scholar]
  13. Fekety R., Silva J., Buggy B., Deery H. G. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):97–102. doi: 10.1093/jac/14.suppl_d.97. [DOI] [PubMed] [Google Scholar]
  14. Fekety R., Silva J., Toshniwal R., Allo M., Armstrong J., Browne R., Ebright J., Rifkin G. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis. 1979 Mar-Apr;1(2):386–397. doi: 10.1093/clinids/1.2.386. [DOI] [PubMed] [Google Scholar]
  15. George W. L. Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S208–S213. doi: 10.1093/clinids/6.supplement_1.s208. [DOI] [PubMed] [Google Scholar]
  16. Gerding D. N. Disease associated with Clostridium difficile infection. Ann Intern Med. 1989 Feb 15;110(4):255–257. doi: 10.7326/0003-4819-110-4-255. [DOI] [PubMed] [Google Scholar]
  17. Heard S. R., O'Farrell S., Holland D., Crook S., Barnett M. J., Tabaqchali S. The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. J Infect Dis. 1986 Jan;153(1):159–162. doi: 10.1093/infdis/153.1.159. [DOI] [PubMed] [Google Scholar]
  18. Keighley M. R., Burdon D. W., Arabi Y., Williams J. A., Thompson H., Youngs D., Johnson M., Bentley S., George R. H., Mogg G. A. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J. 1978 Dec 16;2(6153):1667–1669. doi: 10.1136/bmj.2.6153.1667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kim K. H., Fekety R., Batts D. H., Brown D., Cudmore M., Silva J., Jr, Waters D. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981 Jan;143(1):42–50. doi: 10.1093/infdis/143.1.42. [DOI] [PubMed] [Google Scholar]
  20. Lyerly D. M., Krivan H. C., Wilkins T. D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988 Jan;1(1):1–18. doi: 10.1128/cmr.1.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Malamou-Ladas H., O'Farrell S., Nash J. Q., Tabaqchali S. Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol. 1983 Jan;36(1):88–92. doi: 10.1136/jcp.36.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McFarland L. V., Mulligan M. E., Kwok R. Y., Stamm W. E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989 Jan 26;320(4):204–210. doi: 10.1056/NEJM198901263200402. [DOI] [PubMed] [Google Scholar]
  23. Mulligan M. E., George W. L., Rolfe R. D., Finegold S. M. Epidemiological aspects of Clostridium difficile-induced diarrhea and colitis. Am J Clin Nutr. 1980 Nov;33(11 Suppl):2533–2538. doi: 10.1093/ajcn/33.11.2533. [DOI] [PubMed] [Google Scholar]
  24. Newsom S. W., Matthews J., Rampling A. M. Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem. J Antimicrob Chemother. 1985 May;15(5):648–649. doi: 10.1093/jac/15.5.648-a. [DOI] [PubMed] [Google Scholar]
  25. Pantosti A., Luzzi I., Cardines R., Gianfrilli P. Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine. Antimicrob Agents Chemother. 1985 Dec;28(6):847–848. doi: 10.1128/aac.28.6.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Siegel D. L., Edelstein P. H., Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA. 1990 Feb 16;263(7):979–982. [PubMed] [Google Scholar]
  27. Silva J., Jr, Batts D. H., Fekety R., Plouffe J. F., Rifkin G. D., Baird I. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med. 1981 Nov;71(5):815–822. doi: 10.1016/0002-9343(81)90369-7. [DOI] [PubMed] [Google Scholar]
  28. Swanson R. N., Hardy D. J., Shipkowitz N. L., Hanson C. W., Ramer N. C., Fernandes P. B., Clement J. J. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother. 1991 Jun;35(6):1108–1111. doi: 10.1128/aac.35.6.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tabaqchali S., Holland D., O'Farrell S., Silman R. Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies. Lancet. 1984 Apr 28;1(8383):935–938. doi: 10.1016/s0140-6736(84)92392-4. [DOI] [PubMed] [Google Scholar]
  30. de Lalla F., Privitera G., Rinaldi E., Ortisi G., Santoro D., Rizzardini G. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother. 1989 Jul;33(7):1125–1127. doi: 10.1128/aac.33.7.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. de Lalla F., Santoro D., Rinaldi E., Suter F., Cruciani M., Guaglianone M. H., Rizzardini G., Pellegata G. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria. J Antimicrob Chemother. 1989 Jan;23(1):131–142. doi: 10.1093/jac/23.1.131. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES